The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 02, 2010
Filed:
Nov. 05, 2004
Shaopei Cai, Seattle, WA (US);
Joyce Chou, El Cerrito, CA (US);
Eric Harwood, Seattle, WA (US);
Carla C. Heise, Benicia, CA (US);
Timothy D. Machajewski, Martinez, CA (US);
David Ryckman, Bellevue, WA (US);
Xiao Shang, Bellevue, WA (US);
Marion Wiesmann, Brisbane, CA (US);
Shuguang Zhu, Shoreline, WA (US);
Shaopei Cai, Seattle, WA (US);
Joyce Chou, El Cerrito, CA (US);
Eric Harwood, Seattle, WA (US);
Carla C. Heise, Benicia, CA (US);
Timothy D. Machajewski, Martinez, CA (US);
David Ryckman, Bellevue, WA (US);
Xiao Shang, Bellevue, WA (US);
Marion Wiesmann, Brisbane, CA (US);
Shuguang Zhu, Shoreline, WA (US);
Novartis Vaccines and Diagnostics, Inc., Emeryville, CA (US);
Abstract
Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.